title: Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model.
abstract: OBJECTIVE
  The aim of this study was to validate quantitative metabolic response of tumors to a treatment measured by longitudinal 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) micro positron emission tomography (microPET) as a robust tool for preclinical evaluation of new anticancer agents.
  
  
  METHODS
  Severe combined immunodeficiency mice with CWR22 xenografts were intravenously treated with bortezomib (Velcade) at 0.8 mg/kg on days 0, 3, 7, 10, and 14 and imaged with FDG microPET before, during and after treatment. Quantitative indices of tumor FDG uptake were developed.
  
  
  RESULTS
  FDG microPET images successfully revealed the gradual reduction of tumor FDG uptake on day 4 onward despite no absolute tumor shrinkage. The standardized uptake values of FDG in tumors was reduced to 43% of the baseline values. Using the total tumor FDG uptake as the viable tumor burden, we found 86% tumor inhibition, compared to a 55% tumor growth inhibition in tumor volume measurement.
  
  
  CONCLUSIONS
  FDG microPET imaging can provide an additional dimension of the efficacy of anticancer therapies that may otherwise be underestimated by tumor volume measurement.
authors.affiliation: Department of Imaging Sciences/Platform Technology, Millennium Pharmaceuticals, Inc., 45 Sidney St., Cambridge, MA, 02139, USA. yumin.zhang@mpi.com
authors.forename: Yumin
authors.initials: Y
authors.lastname: Zhang
authors.forename: Melissa
authors.initials: M
authors.lastname: Saylor
authors.forename: Shenhua
authors.initials: S
authors.lastname: Wen
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Silva
authors.forename: Mark
authors.initials: M
authors.lastname: Rolfe
authors.forename: Joseph
authors.initials: J
authors.lastname: Bolen
authors.forename: Craig
authors.initials: C
authors.lastname: Muir
authors.forename: Corinne
authors.initials: C
authors.lastname: Reimer
authors.forename: Sudeep
authors.initials: S
authors.lastname: Chandra
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D049109:Cell Proliferation / Q000187:drug effects; D004341:Drug Evaluation; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009929:Organ Size / Q000187:drug effects; D049268:Positron-Emission Tomography / Q000379:methods*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D011829:Radiation Dosage; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D019788:Fluorodeoxyglucose F18; D000069286:Bortezomib